Past, Present, and a Glance into the Future of Multiple Myeloma Treatment

Multiple myeloma (MM) is a challenging hematological cancer which typically grows in bone marrow. MM accounts for 10% of hematological malignancies and 1.8% of cancers. The recent treatment strategies have significantly improved progression-free survival for MM patients in the last decade; however,...

Descripción completa

Detalles Bibliográficos
Autores principales: Elbezanti, Weam Othman, Challagundla, Kishore B., Jonnalagadda, Subash C., Budak-Alpdogan, Tulin, Pandey, Manoj K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056051/
https://www.ncbi.nlm.nih.gov/pubmed/36986514
http://dx.doi.org/10.3390/ph16030415
_version_ 1785016031250481152
author Elbezanti, Weam Othman
Challagundla, Kishore B.
Jonnalagadda, Subash C.
Budak-Alpdogan, Tulin
Pandey, Manoj K.
author_facet Elbezanti, Weam Othman
Challagundla, Kishore B.
Jonnalagadda, Subash C.
Budak-Alpdogan, Tulin
Pandey, Manoj K.
author_sort Elbezanti, Weam Othman
collection PubMed
description Multiple myeloma (MM) is a challenging hematological cancer which typically grows in bone marrow. MM accounts for 10% of hematological malignancies and 1.8% of cancers. The recent treatment strategies have significantly improved progression-free survival for MM patients in the last decade; however, a relapse for most MM patients is inevitable. In this review we discuss current treatment, important pathways for proliferation, survival, immune suppression, and resistance that could be targeted for future treatments.
format Online
Article
Text
id pubmed-10056051
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100560512023-03-30 Past, Present, and a Glance into the Future of Multiple Myeloma Treatment Elbezanti, Weam Othman Challagundla, Kishore B. Jonnalagadda, Subash C. Budak-Alpdogan, Tulin Pandey, Manoj K. Pharmaceuticals (Basel) Review Multiple myeloma (MM) is a challenging hematological cancer which typically grows in bone marrow. MM accounts for 10% of hematological malignancies and 1.8% of cancers. The recent treatment strategies have significantly improved progression-free survival for MM patients in the last decade; however, a relapse for most MM patients is inevitable. In this review we discuss current treatment, important pathways for proliferation, survival, immune suppression, and resistance that could be targeted for future treatments. MDPI 2023-03-08 /pmc/articles/PMC10056051/ /pubmed/36986514 http://dx.doi.org/10.3390/ph16030415 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Elbezanti, Weam Othman
Challagundla, Kishore B.
Jonnalagadda, Subash C.
Budak-Alpdogan, Tulin
Pandey, Manoj K.
Past, Present, and a Glance into the Future of Multiple Myeloma Treatment
title Past, Present, and a Glance into the Future of Multiple Myeloma Treatment
title_full Past, Present, and a Glance into the Future of Multiple Myeloma Treatment
title_fullStr Past, Present, and a Glance into the Future of Multiple Myeloma Treatment
title_full_unstemmed Past, Present, and a Glance into the Future of Multiple Myeloma Treatment
title_short Past, Present, and a Glance into the Future of Multiple Myeloma Treatment
title_sort past, present, and a glance into the future of multiple myeloma treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056051/
https://www.ncbi.nlm.nih.gov/pubmed/36986514
http://dx.doi.org/10.3390/ph16030415
work_keys_str_mv AT elbezantiweamothman pastpresentandaglanceintothefutureofmultiplemyelomatreatment
AT challagundlakishoreb pastpresentandaglanceintothefutureofmultiplemyelomatreatment
AT jonnalagaddasubashc pastpresentandaglanceintothefutureofmultiplemyelomatreatment
AT budakalpdogantulin pastpresentandaglanceintothefutureofmultiplemyelomatreatment
AT pandeymanojk pastpresentandaglanceintothefutureofmultiplemyelomatreatment

Ejemplares similares